AEON · AEON Biopharma, Inc. · Debt
$0.28
-0.01 (-3.79%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these conditions, management has concluded that substantial doubt about our ability to continue as a going concern exists as conditions and events, considered in the aggregate, indicate that it is probable that we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this Report are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$13.17M
Shares
49.88M
Volume · Oct 2
3.23M
Avg daily vol (3M)
8.48M
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent convertible notes payable | 2026-06-30 | USD 1,755,000 | 10-Q filed 2026-08-12 |
| Operating lease liabilities | 2026-06-30 | USD 1,020,000 | 10-Q filed 2026-08-12 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.